{"preliminary_commentary":{"by_channel":{"x_thread":10,"youtube":3,"podcast":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05504720\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"name":"PHERFLOT","nct_id":"NCT05504720","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=pherflot-nct05504720. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Single arm with pembrolizumab (200 mg flat dose over 30 min IV) on day 1, 22 and 43 plus trastuzumab (loading dose 8 mg/kg IV over 90 min at day 1 and maintenance dose 6 mg/kg IV over 30 min) on day 22 and 43 plus FLOT in four 2-week treatment cycles prior to undergoing surgery. Following surgery, patients will receive four further 2-week cycles of pembrolizumab+trastuzumab + FLOT followed by pembrolizumab (200 mg flat dose) and trastuzumab (6 mg/kg) alone for up to 11 further cycles (Q3W).","label":"Pembrolizumab Trastuzumab","type":"EXPERIMENTAL"}],"collaborators":["Merck Sharp & Dohme LLC","Organon Healthcare GmbH"],"completion_date":{"date":"2026-08-05","type":"ACTUAL"},"conditions":["Esophagogastric Adenocarcinoma"],"enrollment":{"count":31,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Pembrolizumab","otherNames":["Keytruda"],"type":"DRUG"},{"name":"Trastuzumab","otherNames":["Ontruzant"],"type":"DRUG"},{"name":"FLOT","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-10","lead_sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","official_title":"Pembrolizumab and Trastuzumab in Combination With FLOT in the Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma - A Phase II Trial of the AIO Study Group - PHERFLOT -","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2026-07-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-free survival after 2 years co-primary endpoint","timeFrame":"2 years after enrolment"},{"measure":"Pathological complete response rate co-primary endpoint","timeFrame":"after surgery, i.e. approx. 12 weeks after enrolment"}],"references":[{"citation":"Stein A, Goekkurt E, Al-Batran SE, Moosmann N, Ettrich TJ, Goetze T, Gruen B, Homann N, Lorenzen S, Hofheinz RD, Rempel V, Siegler G, Muller C, Thiele B, Broering T, Cruz MS, Pauligk C, Binder M, Tintelnot J. Perioperative pembrolizumab, trastuzumab and FLOT in HER2-positive localized esophagogastric adenocarcinoma: a phase 2 trial. Nat Med. 2025 Dec;31(12):4197-4204. doi: 10.1038/s41591-025-03979-y. Epub 2025 Oct 18.","pmid":"41109919","type":"DERIVED"},{"citation":"Tintelnot J, Stein A, Al-Batran SE, Ettrich T, Gotze T, Grun B, Haag GM, Heuer V, Hofheinz RD, Homann N, Broring TS, Cruz MS, Kurreck A, Lorenzen S, Moosmann N, Muller C, Schuler M, Siegler G, Binder M, Gokkurt E. Pembrolizumab and trastuzumab in combination with FLOT in the perioperative treatment of HER2-positive, localized esophagogastric adenocarcinoma-a phase II trial of the AIO study group (AIO STO 0321). Front Oncol. 2023 Oct 16;13:1272175. doi: 10.3389/fonc.2023.1272175. eCollection 2023.","pmid":"37909020","type":"DERIVED"}],"start_date":{"date":"2023-02-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Evaluating Pembrolizumab, Trastuzumab and FLOT as Perioperative Treatment of HER2-positive, Localized Esophagogastric Adenocarcinoma","url":"https://clinicaltrials.gov/study/NCT05504720"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/pherflot-nct05504720"}